SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients

Lupus Nephritis Clinical Trial

Official title:

SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Diabetic and Non- Diabetic Lupus Nephritis Patients

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05704088
• Other study ID #: MD.21.12.574
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: October 8, 2022
• Est. completion date: December 8, 2023

Study information

• Verified date: January 2023
• Source: Mansoura University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this Randomized, controlled trial in 100 patients with LN with an estimated glomerular filtration rate (eGFR) of 25-75 ml/min/1.73m2. Diagnosis of LN was performed by renal biopsy, and all of the renal biopsies were carried out at urology and nephrology center. 1. The main questions it aims to answer are: - Assess the role of sodium glucose co transporter 2 inhibitors (SGLT2i) in regression of ongoing kidney and cardiac diseases among diabetic or non-diabetic patients with lupus nephritis (LN) under different immunosuppressive therapies. - Investigate the impact of SGLT2i on bone and mineral metabolism in these patients. Participants will be randomized into two groups : - Study group: will receive SGLT2i as add on drug or replace another drug according to the patient clinical situation, Dapagliflozin 10 mg will be used once daily with or without food. - Control group: will be maintained on their medication.

Description:

Study sitting: Nephrology and renal transplant unit at urology and nephrology center in Mansoura University. Study design and sample size: Randomized, controlled trial that will include 100 patients with Lupus nephritis (LN) with an estimated glomerular filtration rate of 25-75 ml/min/1.73m2. Diagnosis of LN was performed by renal biopsy, and all of the renal biopsies were carried out at urology and nephrology center. The patients will be randomized into two groups Study group: will receive SGLT2i as add on drug or replace another drug according to the patient clinical situation, Dapagliflozin 10 mg will be used once daily with or without food. Control group: will be maintained on their medication. Study Protocol: Patients in the study group will treated with dapagliflozin initiated at a total daily dosage of 10 mg once daily. Methods: The following data will be gathered and evaluated for all patients: I-before intervention: Patients of both groups will be subjected to full history taking including duration of LN and drug history and routine clinical examination including blood pressure and BMI measurements. Laboratory investigations: Serum creatinine, Creatinine clearance. 24 hour urine protein, urine protein/creatinine ratio. Urine analysis. HBA1c. hemoglobin (HGB). Uric acid and lipid profile. Lupus serology. immunoreactive parathyroid hormone (iPTH). Vitamin D level. Fibroblast growth factor 23 level. bone turnover markers : bone specific alkaline phosphates propeptides of type 1 procollagen tartrate resistant acid phosphatase 5b sclerostin level Radiological investigation: Quantitative computed tomography: to detect bone and mineral density (BMD). Cardiovascular assessment: Echocardiography and vascular calcification incidence (NCCT model) : for detection of coronary calcification. II-after intervention: All patients will be evaluated monthly regarding: Regular measurement of blood pressure each visit. Laboratory investigations: Serum creatinine, creatinine clearance. 24 hour proteinuria, protein/creatinine ratio. Fasting, random and postprandial glucose levels. calcineurin inhibitors (CNI) trough level if used. Urine analysis. HGB level. Uric acid, lipid profile. Lupus serology. All patients will be evaluated every 3 month regarding: 1. iPTH 2. Vitamin D level All patients will be evaluated at 12 month regarding: 1. Fibroblast growth factor 23 level 2. High resolution quantitative computed tomography. 3. Bone turnover markers.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 100
• Est. completion date: December 8, 2023
• Est. primary completion date: October 8, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age of patient is more than 18.
• Patients who are willing to sign informed consent.
• Patients with SLE diagnosed according to EULAR/ACR classification criteria.
• Patients with LN according to renal biopsy.
• Patients with eGFR > 30 ml/min/1.73m2.

Exclusion Criteria:

• With eGFR <30 ml/min per 1.73 m2.
• Who is currently pregnancy or lactation.
• With medical history of chronic disease (chronic liver disease, cancer, severe respiratory distress, gastrointestinal tract lesions).
• Refuse to participate in the study or lost follow up.
• With evidence of urinary obstruction of difficulty in voiding at screening.
• Who are receiving high dose diuretics or combined angiotensin-converting enzyme inhibitor (ACEI) and Angiotensin II receptor blockers (ARBS).
• Who have frequent hypotensive episode or systolic blood pressure <100 mmHg. Active malignancy.
• Active infection including HIV.
• Any medications that may affect or interact with bone metabolism such as calcitonin, , denosumab, estrogen and fluoride during the last 6 months.
• Current or previous organ transplantation, or expected to get a kidney transplant within 12 months

Related Conditions & MeSH terms

• BMD
• Lupus Nephritis
• Nephritis

Intervention

Drug:
• Dapagliflozin tablet
randomized control trial, study group will receive dapagliflozin tablets
• placebo
randomized control trial, control group will receive placebo tablets

Locations

Country	Name	City	State
Egypt	Urology and Nephrology Center	Mansoura

Sponsors (1)

Lead Sponsor	Collaborator
Mansoura University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	effect of dapagliflozin on renal function	Effect of dapagliflozin on eGFR (ml/ min).	1 year
Primary	effect of dapagliflozin on kidney function	Effect of dapagliflozin on s.creatinine (mg/dl).	1 year
Primary	effect of dapagliflozin on BMD	Effect of dapagliflozin on osteoporosis using Qct	1 year
Primary	effect of dapagliflozin on minerals	Effect of dapagliflozin on serum calcium and phosphorus (mg/dl)	1 year
Primary	effect of dapagliflozin on Bone	Effect of dapagliflozin on bone turnover markers (ng/dl)	1 year
Secondary	effect of dapagliflozin on blood pressure	measuring systolic and diastolic blood pressure mmgh before and after intervention	1 year
Secondary	effect of dapagliflozin on body weight	assessing body weight in kg before and after intervention	1 year